Highlights of This Issue 5145

SPECIAL FEATURES

CCR Translations

5147 Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier! Maria G. Castro, Gregory J. Baker, and Pedro R. Lowenstein

See related article, p. 5290

CCR New Strategies

5150 New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances Joyce Liu and Ursula A. Matulonis

Molecular Pathways

5157 Molecular Pathways: Myeloid Complicity in Cancer Ingunn M. Stromnes, Philip D. Greenberg, and Sunil R. Hingorani

CCR Focus

5172 The Lymphoma Medicine Cabinet Susan E. Bates

5173 Putting the Clinical and Biological Heterogeneity of Non-Hodgkin Lymphoma into Context Owen A. O’Connor and Kensei Tobinai

5182 Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype Kieron Dunleavy, Mark Roschewski, and Wyndham H. Wilson

5194 New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature? Martin Dreyling, Simone Ferrero, Niklas Vogt, and Wolfram Klappler on behalf of the European Mantle Cell Lymphoma Network

5207 Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas Emanuele Zucca, Francesco Bertoni, Barbara Vannata, and Franco Cavalli

5217 Human T-cell Lymphotrophic Virus Type I-Associated Adult T-cell Leukemia–Lymphoma: New Directions in Clinical Research Kunihiro Tsukasaki and Kensei Tobinai

5226 Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma? Emmanuel Bachy and Gilles Salles

5240 Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice Owen A. O’Connor, Govind Bhagat, Karthik Ganapathi, Martin Bjerregaard Pedersen, Francesco D’Amore, Dejan Radeski, and Susan E. Bates

CANCER THERAPY: CLINICAL

5255 A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies Timothy S. Pardee, King Lee, John Luddy, Claudia Maturo, Robert Rodríguez, Scott Isom, Lance D. Miller, Kristin M. Stadelman, Denise Levitan, David Hurd, Leslie R. Ellis, Robin Harrelson, Megan Manuel, Sarah Dralle, Susan Lyerly, and Bayard L. Powell

PERSONALIZED MEDICINE AND IMAGING

5265 Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer Lajos Pusztai, Stacy Moulder, Mehmet Altan, Danielle Kwiatkowski, Vicente Valero, Naoto T. Ueno, Francisco J. Esteva, Rony Avritscher, Yuan Qi, Lewis Strauss, Gabriel N. Hortobágyi, Christos Hatzis, and W. Fraser Symmans
5272 Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort
Trine Tramm, Hayat Mohammed, Simen Myhré, Marianne Kyndt, Jan Alsner, Anne-Lise Borresen-Dale, Therese Sørlie, Arnoldo Frigessi, and Jens Overgaard

5281 Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer
Kenneth H. Yu, Mark Ricigliano, Manuel Hidalgo, Ghassan K. Abou-Alfa, Maeve A. Lowery, Leonard B. Saltz, Joseph F. Crotty, Kristen Gary, Brandon Cooper, Rena Lapidus, Mariola Sadowska, and Eileen M. O'Reilly

CANCER THERAPY: PRECLINICAL

5290 Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright, Alan L. Chang, Mahua Dey, Irina V. Balyasnikova, Chung Kwon Kim, Alex Tobias, Yu Cheng, Julius W. Kim, Jian Qiao, Lingjiao Zhang, Yu Han, and Maciej S. Lesniak
See related commentary, p. 5147

5311 Identification of Differentially Expressed Long Noncoding RNAs in Bladder Cancer
Stefan Peter, Edyta Borkowska, Ross M. Drayton, Callum P. Rakhit, Aidan Noon, Wei Chen, and James WF Catto

5322 Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

BIOLOGY OF HUMAN TUMORS

5302 Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics
Jing Xia, Bruce J. Trock, Roman Gulati, Leslie Mallinger, Matthew R. Cooperberg, Peter R. Carroll, H. Ballentine Carter, and Ruth Etzioni

5331 Smoking and Risk of Low- and High-Grade Prostate Cancer: Results from the REDUCE Study
Tammy Ho, Lauren E. Howard, Adriana C. Vidal, Leah Gerber, Daniel Moreira, Madeleine McKeever, Gerald Andriolo, Ramiro Castro-Santamaria, and Stephen J. Freedland

CORRECTION

5339 Correction: Targeting miR21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
ABOUT THE COVER

The cover shows the expression of long noncoding RNAs in normal and malignant bladder urothelium as detected by microarray. Unsupervised hierarchical clustering reveals discrimination of normal, low-grade and high-grade malignant tissues. For details, see the article by Peter and colleagues on page 5311 of this issue.
Clinical Cancer Research

20 (20)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/20

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.